Companies
Giant Biogene
a Hong Kong-listed recombinant-collagen producer behind the consumer brand Kefumei (可复美), which had its second recombinant-collagen implant medical device approved in China in 2026, extending beyond topical cosmetics into medical aesthetics.
- Country
- China
recombinant-collagen
cn
Coverage
| CN | EU | US | |
|---|---|---|---|
| fibers-textiles | ✓ | ✓ | ✓ |
| specialty-fine-chem | ✓ | ✓ | ✓ |
Regulatorsfdaemanmpareach
Verifiable facts
| Fact | Value | Source |
|---|---|---|
| Funding | $70 million (HK IPO) | beautymatter.com |
| Headcount | 2,201 employees (as of 2025-12-31) | minichart.com.sg · vcbeathealth.com |
| Revenue | RMB 5,518.5 million (2025) | hkexnews.hk · minichart.com.sg |
| Capacity | 10,880 kg (recombinant collagen) and 212,500 kg (new manufacturing facilities capacity) | hk-official.cmbi.info · vcbeathealth.com |
| Certification | ISO13485, ISO22716, and US FDA CFSAN | ir.xajuzi.com · xajuzi.com |
| Regulatory approval | Cross-linked Recombinant Collagen Implant (neck wrinkles, June 2026), Recombinant Type I α1 Subtype Collagen Freeze-dried Fibers (2025), and Composite Solution (2026) | hk-official.cmbi.info · hkexnews.hk · www1.hkexnews.hk |
| Production site | Xi'an, Shaanxi Province (Hi-tech Industries Development Zone) | hk-official.cmbi.info · ir.xajuzi.com · www1.hkexnews.hk |
Independent sources: beautymatter.com · hk-official.cmbi.info · hkexnews.hk · ir.xajuzi.com · minichart.com.sg · vcbeathealth.com · www1.hkexnews.hk · xajuzi.com
Technologies
| Name | Cluster | Risk | |
|---|---|---|---|
| Cosmetics, nutricosmetics & wellness | specialty-fine-chem | Low | → |
| Recombinant collagen for cosmetics | fibers-textiles | Medium | → |
Compiled by BIOECON from primary sources.
Compliance
Bioecon is an information intermediary; it is not a regulator, a certification body, or a legal advisor. When working with public-sector customers (procurement under 44-FZ / 223-FZ), Bioecon acts solely as an independent analytical platform, with no remuneration from suppliers.